Zhejiang Jianfeng Group Co. Ltd. Class A

Zhejiang Jianfeng Group Co. Ltd. Class A

SSSE:600668
6.22
CNY
-0.16
(-2.51%)
-0.78EPS
3.08BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.25
5.45
5.43
5.77
6.83
8.14
8.61
7.87
9.23
8.66
6.94
6.93
6.23
5.68
Basic EPS, GAAP
0.49
0.68
0.48
0.69
0.84
1.42
1.76
1.42
2.24
0.7
0.23
0.26
1
-0.69
Free Cash Flow per Basic Share
-0.15
0.39
-0.06
0.8
0.78
1.3
0.42
0.13
0.42
-0.18
-0.47
0.18
-1.1
- -
Dividend per Share
0.23
0.26
0.32
0.23
0.3
0.17
0.31
0.3
0.36
0.45
0.16
0.13
0.14
0.15
Book Value per Share
4.21
4.99
5.25
5.78
6.36
7.66
9.18
10.74
12.61
12.56
12.37
12.56
13.33
12.98
Tangible Book Value per Share
3.69
4.44
4.74
5.28
5.81
6.89
8.26
9.75
11.67
10.98
10.83
10.86
11.67
10.08
Basic Weighted Avg Shares
410
414
416
412
414
413
412
413
412
411
417
415
412
423
Sales/Revenue/Turnover
2,151
2,257
2,259
2,379
2,827
3,362
3,548
3,247
3,805
3,560
2,893
2,876
2,568
2,402
Operating Margin (%)
8.71
11.18
8.04
11.04
16.09
20.72
19.95
17.88
14.68
9.43
4.09
6.79
1.82
-2.9
Depreciation Expense
81
87
99
107
110
117
128
144
179
201
223
276
285
- -
Net Income, GAAP
202
283
201
285
348
589
725
584
924
288
94
108
412
-293
Effective Tax Rate (%)
16.11
16.25
18.58
17.23
21.99
20.37
15.76
14.42
17.45
23.89
33.04
34.13
11.92
- -
Profit Margin (%)
9.37
12.54
8.9
11.99
12.33
17.5
20.43
18
24.29
8.08
3.24
3.75
16.04
-12.22
Working Capital
-237
169
148
8
-61
172
350
252
253
-175
-19
-395
-190
-527
LT Debt
383
681
596
574
253
100
200
92
66
25
352
17
28
36
Total Equity
1,896
2,237
2,324
2,552
2,824
3,450
4,080
4,721
5,511
5,585
5,469
5,532
5,848
5,637
Return on Invested Capital (%)
9.46
10.32
5.95
9.01
11.42
17.61
18.85
13.05
18.36
5.57
1.43
2.26
6.26
- -
Return on Capital (%)
8.78
9.81
6.87
9.06
10.02
14.24
15.84
11.15
15.63
4.35
1.85
1.64
7.14
- -
Return on Common Equity (%)
12.4
14.9
9.51
12.53
13.9
20.33
20.85
14.21
19.17
5.54
1.82
2.1
7.7
-5.29

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
787
798
843
LT Borrowings
35
34
34
LT Finance Leases
- -
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
413
413
413
Market Capitalization
4,274
3,010
3,080

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,417
1,401
1,368
Cash, Cash Equivalents & STI
222
240
205
Accounts Receivable, Net
262
260
260
Inventories
379
387
385
Total Current Liabilities
1,746
1,854
1,895
Payables & Accruals
- -
- -
- -
ST Debt
787
798
843
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.95%
4.57%
5.72%
Free Cash Flow
-211.83%
-123.9%
-715.9%
Net Income, GAAP
35.53%
43.69%
281.43%
Sales/Revenue/Turnover
2.08%
-3.86%
-10.74%
Total Cash Common Dividend
-0.11%
-7.31%
3.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
602
757
663
854
2,876
2025
584
715
- -
648
2,568
2026
537
628
589
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.11
0.06
0.09
0.26
2025
1.41
0.07
- -
-0.58
1
2026
-0.04
0.02
-0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.01
0.09
0.02
0.13
2025
0.01
0.01
- -
0.02
0.14
2026
0.01
0.02
0.1
- -
- -

Company Description

CEO
Jian Hong Yu
Full Time Employees
1,836
Sector
Non-energy minerals
Industry
Construction materials
Address
No. 88, Wujiang East Road Jinhua ZH China 321000
IPO Date
Jul 28, 1993
Business
Zhejiang Jianfeng Group Co., Ltd. (600668.SS) manufactures and distributes cement and pharmaceuticals in China, supplemented by health products, trade logistics, cables and hazardous chemicals. The company produces ordinary Portland cement, Portland slag cement, cement clinkers, silica cements; pharmaceuticals including cefmenoxime hydrochloride for injection, aspartate amlodipine tablets, paroxetine hydrochloride tablets, aceclofenac sustained-release tablets, sodium hyaluronate eye drops, olopatadine hydrochloride eye drops, antibiotics, cardiovascular and cerebrovascular drugs, antidepressants and ophthalmology drugs; health products such as grape seed extract, ginseng extract, apple extract anthocyanins, polyphenols, fruit and vegetable powders, broken fungus spore powder, lyophilized Tianma pieces, Sangge tea, black soya bean drinks, astragalus tablets and various soft capsules; cables including SYWV-75 series physical foamed cables, RVV series cables, network lines, HYA series communication cables and BV insulated wires. Its building materials operations span Zhejiang, Hubei, Yunnan and Guizhou provinces through subsidiaries such as Daye Jianfeng Cement Co., Ltd., while pharmaceutical distribution and retail focus on Zhejiang hospitals and patients via Jinhua Medicine Co., Ltd. and subsidiaries; health products serve domestic and international food, health and cosmetics industries. Founded in 1958 as Jinhua Cement Plant and headquartered at No. 88 Wujiang East Road, Jinhua, Zhejiang Province, the company transformed to a joint-stock system in 1988 and listed on the Shanghai Stock Exchange in 1993 as China's first cement listed firm. Subsidiaries include Zhejiang Jianfeng Pharmaceutical Co., Ltd., Tianjin Jianfeng Natural Products Research and Development Co., Ltd., Shanghai North Cara Medical Technology Co., Ltd. and Zhejiang Jianfeng Health Technology Co., Ltd. In recent developments, a wholly-owned subsidiary plans investment in a 3 million tons annual output production line; the board authorized a share buyback plan in April 2025 and an equity buyback for CNY 40 million; Daye Jianfeng Cement achieved national "green factory" status; and Jianfeng Pharmaceutical rehired Academician Wang Guangji as chief scientist while a subsidiary's esomeprazole product won a national procurement bid.